Tag: Precision medicine

Antisense oligonucleotides (ASOs) have emerged as a significant therapeutic platform, with several drugs already approved by the FDA for the treatment of rare genetic disorders. This innovative technology provides a way to target the root cause of certain diseases at the RNA level, fundamentally changing how various genetic conditions are treated with ASO.

In 2001, the U.S. Food and Drug Administration (FDA) approved imatinib (brand name Gleevec), marking a monumental shift in cancer treatment as it was the first rationally designed kinase inhibitor to directly target a specific cancer-causing protein. Its approval opened the door to a new era of precision medicine, demonstrating that targeted therapy could be a safe and highly effective alternative to conventional chemotherapy.

According to Precedence Research, the market for AI in drug discovery is growing at a rate of 27.38%, demonstrating the rapid integration of this technology into pharmaceutical research. This innovation centers on the concept of an AI drug—a medication designed or identified with the assistance of artificial intelligence.

Biologic drugs often contain thousands of atoms and intricate three-dimensional structures, making them profoundly more complex than chemically synthesized small-molecule drugs like aspirin. This unique composition is a key reason *why are biologics more effective* for treating a wide array of chronic diseases, from autoimmune disorders to cancer. Unlike conventional treatments, biologics are designed to home in on specific targets within the body, leading to more precise and powerful therapeutic outcomes.

KRAS mutations are found in approximately 23% of non-small cell lung cancers (NSCLC), with the G12C mutation being the most common subtype. Lumakras, known generically as sotorasib, was the first FDA-approved targeted therapy designed specifically to address this previously 'undruggable' mutation, and its mechanism of action is both selective and irreversible.

Developing a new drug can take over 13.5 years and cost billions [1.5.5]. So, **what is the drug tensor?** It is not a single medication, but an advanced computational concept using artificial intelligence to dramatically accelerate and refine this process [1.5.1, 1.4.1].

Basket trials have revolutionized modern oncology, allowing researchers to test a single drug's efficacy across multiple cancer types that share a specific genetic mutation. However, the term "what is the drug basket method?" also refers to an entirely separate, historical system for hospital pharmacy drug distribution, highlighting the importance of context when encountering this phrase.

Over 90% of people have at least one genetic variation that can influence their response to medication. PGx, or pharmacogenomics, is the study of how an individual's genetic makeup affects their reaction to drugs, helping to move healthcare towards a more personalized approach.